Regulatory Intelligence
Topic | Replies | Views | Activity | |
---|---|---|---|---|
About the Regulatory Intelligence category
|
![]() |
0 | 255 | August 3, 2023 |
FDA Requirement to inform about nitrosamine risk in ongoing/new clinical trials
|
![]() ![]() ![]() |
2 | 192 | December 13, 2024 |
Variation for new spec due to updated EMA Guideline
|
![]() ![]() ![]() |
7 | 604 | July 16, 2024 |
Regulatory Differences between EMA and FDA on Nitrosamines
|
![]() ![]() |
1 | 469 | June 25, 2024 |
Entidades regulatorias y su postura en el análisis de nitrosaminas en estudios de estabilidad de preparados farmacéuticos
|
![]() |
0 | 245 | February 28, 2024 |
Adoption of CPCA beyond FDA/ EMA
|
![]() ![]() ![]() ![]() ![]() |
9 | 1005 | January 31, 2024 |
Would we expect new regulations evolution for "PFAS" similar to what the industry had for Nitrosamines since 2018?
|
![]() ![]() |
1 | 416 | December 19, 2023 |
Risk for dossier submission link to secondary amine present on API related impurity
|
![]() |
0 | 364 | December 8, 2023 |